Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Biogen Inc. closed 46.82% short of its 52-week high of $238.00, which the company achieved on July 12th.

Biogen's BIIB -3.42% Get Free Report short percent of float has risen 13.95% since its last report. The company recently reported that it has 3.80 million shares sold short, which is 3.35% of all ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Historically, optic nerve involvement has been excluded from MS diagnostic criteria, but its inclusion in the new iteration ...

Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented ...

Biogen Inc. (NASDAQ:BIIB) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Biogen Inc.

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots ...

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...